于一,赵迎新,史冬梅,刘宇扬,刘晓丽,贾硕,吴思婧,孙岩,周玉杰

• 1:首都医科大学附属北京安贞医院心内科北京市心肺血管疾病研究所

摘要(Abstract)：

<正>目前,针对冠心病的治疗,形成了从生活方式的改善到理想化的药物治疗,再到内科介入治疗和外科手术治疗的优化体系。在这一体系中,心脏支架扮演着重要的角色。30余年来,支架经历了从无到有,再到广泛使用的过程,经历了四次技术革命~([1])。1冠状动脉介入治疗的四次技术革命1977年Gruentzig教授完成了世界上首例经皮冠状动脉腔内血管成形术(percutaneous transluminal coronary

关键词(KeyWords)： 经皮冠状动脉介入治疗;生物可吸收支架;药物洗脱支架;裸金属支架

Abstract:

Keywords:

基金项目(Foundation): 北京市医院管理局临床医学发展专项(ZYLX201303);北京市医院管理局“登峰”计划专项(DFL20150601);; 国家临床重点专科建设项目(2013—2014年度)

作者(Author): 于一,赵迎新,史冬梅,刘宇扬,刘晓丽,贾硕,吴思婧,孙岩,周玉杰

参考文献(References)：

• [1]周玉杰.心血管介入治疗的新思路和新技术.心血管病学进展,2012,33(6):685-687.
• [2]Grüntzig A.Transluminal dilatation of coronary-artery stenosis.Lancet,1978,1(1):263.
• [3]周学敏,吕慧,朱国斌.生物可吸收支架临床研究进展.中国介入心脏病学杂志,2015,23(11):643-646.
• [4]Lau KW,Sigwart U.The current status of intracoronary stent:an overview.Singapore Med J.1992,33(2):143-149.
• [5]Hoffmann R,Mintz GS,Dussaillant GR,et al.Patterns and mechanisms of in-stent restenosis.A serial intravascular ultrasound study.Circulation,1996,94(6):1247-1254.
• [6]Fontes I,Barrow D.From sirolimus to the Cypher stent:stages of the victory against restenosis.Ann Cardiol Angeiol(Paris).2004,53 Suppl 1:3s-8s.
• [7]Lagerqvist B,James SK,Stenestrand U,et al.Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.N Engl J Med,2007,356(10):1009-1019.
• [8]周力,孙颖,陈晖.全吸收式生物可降解支架在冠心病介入治疗中的应用.中国介入心脏病学杂志,2014,22(4):262-264.
• [9]Ormiston JA,Serruys PW,Regar E,et al.A bioabsorbableeverolimuseluting coronary stent system for patients with single de-novo coronary artery lesions(ABSORB):a prospective open-label trial.Lancet,2008,371(9616):899-907.
• [10]Serruys PW,Ormiston JA,Onuma Y,et al.A bioabsorbableeverolimus-eluting coronary stent system(ABSORB):2-year outcomes and results from multiple imaging methods.Lancet,2009,373(9667):897-910.
• [11]Onuma Y,Dudek D,Thuesen L,et al.Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease:the ABSORB cohort A trial.JACC Cardiovasc Interv,2013,6(10):999-1009.
• [12]Nakatani S,Onuma Y,Ishibashi Y,et al.Early(before 6months),late(6-12 months)and very late(after 12 months)angiographic scaffold restenosis in the ABSORB Cohort B trial.Euro Intervention,2015,10(11):1288-1298.
• [13]Bourantas CV,Farooq V,Zhang Y,et al.Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation:a substudy of the ABSORB Cohort B Clinical Trial.Euro Intervention,2015,10(11):1299-1306.
• [14]Abizaid A,Ribamar Costal J,Bartorelli AL,et al.The ABSORB EXTEND study:preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled.Euro Intervention,2015,10(12):1396-1401.
• [15]Serruys PW,Chevalier B,Dudek D,et al.A bioresorbableeverolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by denovo native coronary artery lesions(ABSORBⅡ):an interim1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.Lancet,2015,385(9962):43-54.
• [16]Chevalier B.The 2-year clinical outcomes of the ABSORBⅡtrial:firstrandomized comparison between the absorb everolimus eluting bioresorbable vascular scaffold and the XIENCE everolimus eluting stent[EB/OL].(2015-10-12).http://www.clinicaltrialresults.org/Slides/TCT2015/Chevalier_ABSORBⅡ.pdf.
• [17]Ellis SG,Kereiakes DJ,Metzger DC,et al.Everolimus-eluting bioresorbablescaffolds for coronary artery disease.N Engl J Med,2015,373(20):1905-1915.
• [18]Gao R,Yang Y,Han Y,et al.Bioresorbablevascular scaffolds versus metallic stents in patients with coronary artery disease:ABSORB China trial.J Am Coll Cardiol,2015,66(21):2298-2309.
• [19]Kimura T,Kozuma K,Tanabe K,et al.A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs.everolimus-eluting metallic stents in patients with coronary artery disease:ABSORB Japan.Eur Heart J,2015,36(47):3332-3342.
• [20]Puricel S,Arroyo D,Corpataux N,et al.Comparison of everolimus-and biolimus-eluting coronary stents with everolimuseluting bioresorbable vascular scaffolds.J Am Coll Cardiol,2015,65(8):791-801.
• [21]Capodanno D,Gori T,Nef H,et al.Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice:early and midterm outcomes from the European multicentre GHOST-EU registry.Euro Intervention,2015,10(10):1144-1153.
• [22]Lotan C,Meredith IT,Mauri L,et al.Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice:12-month data from the E-Five registry.JACC Cardiovasc Interv,2009,2(12):1227-1235.
• [23]Krucoff MW,Rutledge DR,Gruberg L,et al.A new era of prospective real-world safety evaluation primary report of XIENCE V USA(XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study).JACC Cardiovasc Interv,2011,4(12):1298-1309.
• [24]Tamburino C,Capranzano P,Gori T,et al.1-year outcomes of everolimus-eluting bioresorbablescaffolds versus everolimuseluting stents:apropensity-matched comparison of the GHOSTEU and XIENCE V USA registries.JACC Cardiovasc Interv,2016,9(5):440-444.
• [25]SabatéM,Windecker S,I1iguez A,et al.Everolimus-eluting bioresorbable stent vs.durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction:results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFIⅡtrial.Eur Heart J,2016,37(3):229-240.
• [26]Kereiakes DJ,Meredith IT,Windecker S,et al.Efficacy and safety of a novel bioabsorbablepolymer-coated,everolimus-eluting coronary stent:the EVOLVEⅡRandomized Trial.Circ Cardiovasc Interv,2015,8(4).
• [27]Haude M,Ince H,Abizaid A,et al.Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions(BIOSOLVE-Ⅱ):6month results of a prospective,multicentre,non-randomised,first-in-man trial.Lancet,2016,387(10013):31-39.
• [28]Haude M,Ince H,Abizaid A,et al.Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions:12-month clinical results and angiographic findings of the BIOSOLVE-Ⅱfirst-in-man trial.Eur Heart J,2016.[Epub ahead of print]
• [29]Wu Y,Shen L,Wang Q,et al.Comparison of acute recoil between bioabsorbable poly-L-lactic acid XINSORB stent and metallic stent in porcine model.J Biomed Biotechnol,2012,2012:413956.
• [30]Chen JH,Wu YZ,Shen L,et al.First-in-man implantation of the XINSORB bioresorbablesirolimus-eluting scaffold in China.Chin Med J(Engl),2015,128(9):1275-1276.
• [31]Wu Y,Shen L,Ge L,et al.Six-month outcomes of the XINSORB bioresorbablesirolimus-eluting scaffold in treating single de novo lesions in human coronary artery.Catheter Cardiovasc Interv,2016,87(Suppl 1):630-637.
• [32]Cassese S,Byrne RA,Ndrepepa G,et al.Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents:a meta-analysis of randomised controlled trials.Lancet,2016,387(10018):537-544.
• [33]Lipinski MJ,Escarcega RO,Baker NC,et al.Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbablevascular scaffold:asystematic review and Metaanalysis.JACC Cardiovasc Interv,2016,9(1):12-24.